Processing

Please wait...

Settings

Settings

Goto Application

1. WO2009112845 - AMIDO-THIOPHENE COMPOUNDS AND THEIR USE

Publication Number WO/2009/112845
Publication Date 17.09.2009
International Application No. PCT/GB2009/000686
International Filing Date 13.03.2009
IPC
C07D 333/38 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
333Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
02not condensed with other rings
04not substituted on the ring sulfur atom
26with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
38Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
A61K 31/381 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
38having sulfur as a ring hetero atom
381having five-membered rings
C07D 409/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
04directly linked by a ring-member-to-ring- member bond
C07D 409/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
C07D 409/14 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
409Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
14containing three or more hetero rings
C07D 413/06 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
413Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
02containing two hetero rings
06linked by a carbon chain containing only aliphatic carbon atoms
CPC
A61P 1/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
A61P 1/16
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
16for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
A61P 1/18
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
1Drugs for disorders of the alimentary tract or the digestive system
18for pancreatic disorders, e.g. pancreatic enzymes
A61P 11/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
A61P 11/06
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
11Drugs for disorders of the respiratory system
06Antiasthmatics
A61P 17/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
17Drugs for dermatological disorders
Applicants
  • THE UNIVERSITY OF EDINBURGH [GB]/[GB] (AllExceptUS)
  • WEBSTER, Scott, Peter [GB]/[GB] (UsOnly)
  • SECKL, Jonathan, Robert [GB]/[GB] (UsOnly)
  • WALKER, Brian, Robert [GB]/[GB] (UsOnly)
  • WARD, Peter [GB]/[GB] (UsOnly)
  • PALLIN, Thomas, David [GB]/[GB] (UsOnly)
  • DYKE, Hazel, Joan [GB]/[GB] (UsOnly)
  • PERRIOR, Trevor, Robert [GB]/[GB] (UsOnly)
Inventors
  • WEBSTER, Scott, Peter
  • SECKL, Jonathan, Robert
  • WALKER, Brian, Robert
  • WARD, Peter
  • PALLIN, Thomas, David
  • DYKE, Hazel, Joan
  • PERRIOR, Trevor, Robert
Agents
  • WYTENBURG, Wilhelmus
Priority Data
0804685.613.03.2008GB
61/036,11113.03.2008US
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) AMIDO-THIOPHENE COMPOUNDS AND THEIR USE
(FR) COMPOSÉS AMIDO-THIOPHÈNE ET LEUR UTILISATION
Abstract
(EN) The present invention pertains generally to the field of therapeutic compounds. More specifically the present invention pertains to certain amido-thiophene compounds that, inter alia, inhibit 11 β-hydroxysteroid dehydrogenase type 1 (11 β-HSD1 ). The present invention also pertains to pharmaceutical compositions comprising such compounds, and the use of such compounds and compositions, both in vitro and in vivo, to inhibit 11 β-hydroxysteroid dehydrogenase type 1; to treat disorders that are ameliorated by the inhibition of 11 β-hydroxysteroid dehydrogenase type 1; to treat the metabolic syndrome, which includes disorders such as type 2 diabetes and obesity, and associated disorders including insulin resistance, hypertension, lipid disorders and cardiovascular disorders such as ischaemic (coronary) heart disease; to treat CNS disorders such as mild cognitive impairment and early dementia, including Alzheimer's disease; etc.
(FR) La présente invention concerne généralement le domaine des composés thérapeutiques. La présente invention concerne plus spécifiquement certains composés amido-thiophène qui, entre autres, inhibent la 11 β-hydroxystéroïde déshydrogénase de type 1 (11 β-HSD1 ). La présente invention concerne également des compositions pharmaceutiques comprenant ces composés, et l'utilisation de ces composés et de ces compositions, in vitro et in vivo, pour inhiber la 11 β-hydroxystéroïde déshydrogénase de type 1; pour traiter les troubles qui sont améliorés par l'inhibition de la 11 β-hydroxystéroïde déshydrogénase de type 1; pour traiter le syndrome métabolique, qui comprend des troubles tels que le diabète de type 2 et l'obésité, et les troubles associés comprenant l'insulinorésistance, l'hypertension, les troubles lipidiques et les troubles cardiovasculaires tels que la cardiopathie ischémique (maladie coronarienne); pour traiter les troubles du SNC tels que le trouble cognitif modéré et la démence précoce, y compris la maladie d'Alzheimer; etc.
Latest bibliographic data on file with the International Bureau